

COVID-19 Vaccine Information for People with CancerNational Comprehensive
Cancer Network®

Search

[Home](#) > [Guidelines](#) > **Treatment by Cancer Type**

NCCN Guidelines

[Treatment by Cancer Type](#)**[Detection, Prevention, and Risk Reduction](#)****[Supportive Care](#)****[Specific Populations](#)****[Guidelines for Patients](#)****[Guidelines With Evidence Blocks](#)****[Framework for Resource Stratification](#)****[Harmonized Guidelines](#)****[International Adaptations and Translations](#)****[Guidelines Process](#)** +**[Guidelines Panels and Disclosure](#)** +**[Submissions, Licensing, and Permissions](#)** +**[Recently Updated Guidelines](#)**

Treatment by Cancer Type

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are posted with the latest update date and version number.

[Acute Lymphoblastic Leukemia](#)

Version: 2.2021

[Acute Myeloid Leukemia](#)

Version: 3.2021

[Anal Carcinoma](#)

Version: 2.2021

[Basal Cell Skin Cancer](#)

Version: 2.2021

[B-Cell Lymphomas](#)

Version: 4.2021

[Bladder Cancer](#)

Version: 4.2021

[Bone Cancer](#)

Version: 1.2022

[Breast Cancer](#)

Version: 5.2021

[Central Nervous System Cancers](#)

Version: 1.2021

[Cervical Cancer](#)

Version: 1.2021

[Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](#)

Version: 4.2021

[Chronic Myeloid Leukemia](#)

Version: 3.2021

[Colon Cancer](#)

Version: 2.2021

[Dermatofibrosarcoma Protuberans](#)

Version: 1.2021

[Esophageal and Esophagogastric Junction Cancers](#)

Version: 4.2021

[Gastric Cancer](#)

Version: 4.2021

[Gastrointestinal Stromal Tumors \(GIST\)](#)

Version: 1.2021

[Gestational Trophoblastic Neoplasia](#)

Version: 2.2021

[Hairy Cell Leukemia](#)

Version: 2.2021

[Head and Neck Cancers](#)

Version: 3.2021

[Hepatobiliary Cancers](#)

Version: 3.2021

[Histiocytic Neoplasms](#)

Version: 1.2021

[Hodgkin Lymphoma](#)

Version: 4.2021

[Kaposi Sarcoma](#)

Version: 2.2021

[Kidney Cancer](#)

Version: 1.2022

[Malignant Pleural Mesothelioma](#)

Version: 2.2021

[Melanoma: Cutaneous](#)

Version: 2.2021

[Melanoma: Uveal](#)

Version: 2.2021

[Merkel Cell Carcinoma](#)

Version: 1.2021

[Multiple Myeloma](#)

Version: 7.2021

[Myelodysplastic Syndromes](#)

Version: 3.2021

[Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes](#)

Version: 4.2021

[Myeloproliferative Neoplasms](#)

Version: 1.2021

[Neuroendocrine and Adrenal Tumors](#)

Version: 2.2021

[Non-Small Cell Lung Cancer](#)

Version: 5.2021

[Occult Primary](#)

Version: 2.2021

[Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer](#)

Version: 1.2021

[Pancreatic Adenocarcinoma](#)

Version: 2.2021

[Pediatric Acute Lymphoblastic Leukemia](#)

Version: 3.2021

[Pediatric Aggressive Mature B-Cell Lymphomas](#)

Version: 2.2021

[Pediatric Hodgkin Lymphoma](#)

Version: 3.2021

[Penile Cancer](#)

Version: 2.2021

[Primary Cutaneous Lymphomas](#)

Version: 2.2021

[Prostate Cancer](#)

Version: 2.2021

[Rectal Cancer](#)

Version: 1.2021

[Small Bowel Adenocarcinoma](#)

Version: 1.2021

[Small Cell Lung Cancer](#)

Version: 3.2021

[Soft Tissue Sarcoma](#)

Version: 2.2021

[Squamous Cell Skin Cancer](#)

Version: 1.2021

[Systemic Light Chain Amyloidosis](#)

Version: 1.2022

[Systemic Mastocytosis](#)

Version: 3.2021

[T-Cell Lymphomas](#)

Version: 1.2021

[Testicular Cancer](#)

Version: 2.2021

[Thymomas and Thymic Carcinomas](#)

Version: 1.2021

[Thyroid Carcinoma](#)

Version: 1.2021

[Uterine Neoplasms](#)

Version: 3.2021

[Vulvar Cancer](#)

Version: 3.2021

[Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma](#)

Version: 1.2022

[Wilms Tumor \(Nephroblastoma\)](#)

Version: 2.2021

The NCCN Guidelines are copyrighted by the NCCN. All rights reserved. NCCN Guidelines and illustrations (including algorithms) may not be reproduced in any form for any purpose without the express written permission of the NCCN. Permissions Requests Section.

NCCN MAKES NO REPRESENTATIONS OR WARRANTIES CONCERNING THE NCCN CONTENT, THE NCCN GUIDELINES OR DERIVATIVE RESOURCES PROVIDED BY NCCN, ALL OF WHICH ARE PROVIDED "AS IS." NCCN DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. NCCN DOES NOT WARRANT THE ACCURACY, APPROPRIATENESS, APPLICABILITY OR COMPLETENESS OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY DERIVATIVE RESOURCES, NOR DOES NCCN MAKE ANY REPRESENTATIONS REGARDING THE USE OR RESULTS OF THE USE OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY SUCH DERIVATIVE RESOURCES.

NCCN EXPLICITLY DISCLAIMS THE APPROPRIATENESS OR APPLICABILITY OF THE NCCN CONTENT, THE NCCN GUIDELINES, AND ANY DERIVATIVE RESOURCES, OR THE USE OR APPLICATION OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY SUCH DERIVATIVE RESOURCES, TO ANY SPECIFIC PATIENT'S CARE OR TREATMENT. ANY CLINICIAN SEEKING TO APPLY OR CONSULT THE NCCN CONTENT, THE NCCN GUIDELINES AND/OR ANY DERIVATIVE RESOURCES IS EXPECTED TO USE INDEPENDENT MEDICAL JUDGMENT IN THE CONTEXT OF THE INDIVIDUAL CLINICAL CIRCUMSTANCES TO DETERMINE ANY PATIENT'S CARE OR TREATMENT.

3025 Chemical Road, Suite 100, Plymouth Meeting, PA 19462

Phone: 215-690-0300 Fax: 215-690-0280

Copyright © 2021 National Comprehensive Cancer Network, All Rights Reserved.

No portion of this Site or any NCCN Content may be copied, transferred, reproduced, modified, or otherwise used for any purpose without NCCN's express written permission.

See [Legal Notices](#) Section for additional notices and terms governing your use of this Site.